Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Allergy Asthma Immunol. 2007 Aug;99(2):190-3.

Effect of omalizumab on patients with chronic urticaria.

Author information

  • 1Division of Clinical Allergy and Immunology, UCLA Medical Center, Los Angeles, California, USA. spector@calallergy.com

Abstract

BACKGROUND:

Chronic urticaria (CU) is often difficult to treat. Approximately 40% to 50% of patients with no apparent cause are believed to have an associated autoimmune profile that may play a pathogenetic role.

OBJECTIVES:

To describe 3 patients with CU refractory to conventional treatment who responded to omalizumab therapy.

METHODS:

Treatment was maximized with antihistamines, antileukotrienes, and histamine2 blockers with no improvement. Systemic steroids provided only temporary relief. Laboratory workup revealed 1 patient with a low IgE level and elevated anti-IgE receptor antibody level, 1 patient with an elevated IgE level but a normal anti-IgE receptor antibody level, and 1 patient with a very elevated IgE level and an elevated anti-IgE receptor antibody level. All 3 patients were prescribed omalizumab therapy every 2 weeks.

RESULTS:

Two patients had total clearing of urticaria within 1 week and 1 patient within 6 weeks of starting omalizumab therapy. The patient with the elevated anti-IgE receptor antibody level had normalization of the level after starting treatment.

CONCLUSIONS:

Omalizumab may have a beneficial effect in the treatment of CU. Further studies are needed to confirm this effect and better elucidate the mechanism for the observed improvement.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk